phrykt

Allogene Therapeutics, Inc. (ALLO): who owns it and who trades it

As of Nov 16, 2026, ALLO insiders reported 15 open-market sales worth $669K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was David D Chang (CEO), with $289K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Allogene Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ALLO

207 funds and institutions reported ALLO shares worth $657M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 12.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.12.4%
Frazier Life Sciences Management, L.P.9.2%
Pfizer Inc9.0%
State Street Corp7.8%
Tpg Gp A, LLC7.7%
Sio Capital Management, LLC5.5%
Primecap Management Co5.4%
Vanguard Capital Management LLC5.0%
FMR LLC (Fidelity)4.9%
Citadel Advisors LLC4.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.30.15M12.37%$62.7M+58%
Frazier Life Sciences Management, L.P.22.45M9.21%$46.7M+491%
Pfizer Inc22.03M9.04%$46.9MNo change
State Street Corp19.03M7.80%$39.6M+120%
Tpg Gp A, LLC18.72M7.68%$38.9MNo change
Sio Capital Management, LLC13.32M5.47%$27.7M–
Primecap Management Co13.12M5.38%$27.3M+57%
Vanguard Capital Management LLC12.17M4.99%$25.3M+76%
FMR LLC (Fidelity)12.01M4.93%$25M+655%
Citadel Advisors LLC10.09M4.14%$21M+48%
Two Sigma Investments, LP7.78M3.19%$16.2M+45%
Geode Capital Management, LLC7.05M2.89%$14.7M+71%
Goldman Sachs Group Inc6.15M2.52%$12.8M+122%
GordonMD Global Investments LP5.30M2.17%$11M+270%
Marshall Wace, LLP5.10M2.09%$10.6M+48%
Patient Square Capital LP5.05M2.07%$10.5M+46%
Aberdeen Group plc5.00M2.05%$10.4M+242%
Millennium Management LLC4.84M1.99%$10.1M+46%
D. E. Shaw & Co., Inc.4.71M1.93%$9.8M+70%
T. Rowe Price Associates4.64M1.90%$9.7M-14%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ALLO insiders reported $0 of open-market purchases and $669K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$669K
15 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 21, 2026
Filed Oct 23, 2026

Purchases and sales by month

$337K$337KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 21, 2026Geoffrey M. ParkerCFOSale36,342$1.34$48.7KForm 4
Aug 21, 2026Earl Martin DouglasVice presidentSale29,697$2.12$63KForm 4
Apr 21, 2026Annie YoshiyamaVice presidentSale9,586$2.31$22.1KForm 4
Mar 31, 2026Benjamin Machinas BeneskiVice presidentSale2,867$2.50$7.2KForm 4
Mar 16, 2026Benjamin Machinas BeneskiVice presidentSale4,835$2.47$11.9KForm 4
Mar 16, 2026David D ChangCEOSale47,763$2.47$118KForm 4
Mar 2, 2026Benjamin Machinas BeneskiVice presidentSale7,132$2.60$18.5KForm 4
Feb 2, 2026Benjamin Machinas BeneskiVice presidentSale7,549$1.73$13.1KForm 4
Feb 2, 2026David D ChangCEOSale95,269$1.80$171KForm 4
Feb 2, 2026Geoffrey M. ParkerCFOSale24,001$1.76$42.2KForm 4
Feb 2, 2026Earl Martin DouglasVice presidentSale22,900$1.76$40.3KForm 4
Feb 2, 2026Annie YoshiyamaVice presidentSale4,167$1.72$7.2KForm 4
Feb 2, 2026Zachary RobertsVice presidentSale35,700$1.77$63.2KForm 4
Jan 21, 2026Zachary RobertsVice presidentSale26,269$1.56$41KForm 4
Nov 17, 2025Benjamin Machinas BeneskiVice presidentSale786$1.22$959Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
David D ChangPresident and CEO, Director–$289KMar 16, 2026
Zachary RobertsEVP of R&D–$104KFeb 2, 2026
Earl Martin DouglasSVP, General Counsel–$103KAug 21, 2026
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER–$90.9KOct 21, 2026
Benjamin Machinas BeneskiSVP, Chief Technical Officer–$51.7KMar 31, 2026
Annie YoshiyamaSVP, Finance–$29.3KApr 21, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ALLO short interest

High short interest. 14.8% of ALLO shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 21%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 51.29M ALLO shares were sold short, 14.8% of the shares outstanding, down 4.0% from the report before. At the average daily volume of 8.27M shares, buying them all back would take about 6.2 trading days (days to cover).

Shares short, % of all shares

14.8%May 15Oct 3027.7%

Days to cover

6.2May 15Oct 3013.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202651.29M14.84%-4%8.27M6.2
Oct 15, 202653.41M15.46%-4%5.78M9.2
Sep 30, 202655.61M16.10%-7%6.18M9.0
Sep 15, 202659.60M17.25%+1%5.30M11.3
Aug 31, 202659.11M17.11%+0%4.87M12.2
Aug 14, 202658.95M17.06%-3%4.94M11.9
Jul 31, 202660.75M24.92%+2%6.58M9.2
Jul 15, 202659.71M24.49%-6%9.40M6.3
Jun 30, 202663.39M26.00%+32%12.33M5.1
Jun 15, 202648.04M19.70%+8%7.74M6.2
May 29, 202644.48M18.25%+5%6.57M6.8
May 15, 202642.28M17.34%+15%6.60M6.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Allogene Therapeutics company events

Allogene Therapeutics filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 2, 2026LeadershipGeoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc., provided notice of his retirement from the Company in all capacities, effective November 6, 2026. Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. Jun 22, 2026AnnouncementThe Company filed a prospectus supplement with the Securities and Exchange Commission relating to sales of shares of its common stock having an aggregate offering price of up to $135.0 million to be sold pursuant to a certain Sales Agreement, dated November 5, 2019, as amended on November 2, 2022… Filing
  5. May 28, 2026LeadershipThe Board of Directors of Allogene Therapeutics, Inc., upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities. Filing
  6. May 13, 2026AgreementAllogene Therapeutics, Inc. entered into (i) a Termination Agreement with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. and (ii) a Second Amended and Restated Shareholders’ Agreement with Overland Therapeutics Inc. and HH BioPharma Holdings Ltd. Pursuant to the Termination… Filing
  7. Apr 15, 2026AnnouncementWe entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 87,500,000 shares of our common stock, par value $0.001 per share. Filing
  8. Apr 13, 2026AnnouncementAllogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. Filing
  9. Apr 13, 2026AnnouncementAllogene Therapeutics, Inc. announced interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel in first-line consolidation for large B-cell lymphoma. Filing
  10. Mar 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Allogene Therapeutics financials

Famous investors that hold ALLO

4 of the 50 well-known investors we track reported holding ALLO in their latest 13F filing. The largest position is Ken Griffin's, worth $39.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202624.56M$39.3M0.0%+143%
Jim Simons · Renaissance TechnologiesQ3 20265.23M$8.4M0.0%+36%
Israel Englander · Millennium ManagementQ3 20265.12M$8.2M0.0%+6%
Steve Cohen · Point72 Asset ManagementQ3 2026368,461$590K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ALLO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Citadel Securities GP LLC13G4.7%
Nov 16, 2026Citadel Securities GP LLC13G4.7%
Nov 10, 2026STATE STREET CORPORATION13G4.7%
Nov 10, 2026STATE STREET CORPORATION13G4.7%
Oct 27, 2026BlackRock, Inc.13G/A6.7%
Oct 27, 2026BlackRock, Inc.13G/A6.7%

Questions about Allogene Therapeutics, Inc. (ALLO) stock

Who owns the most ALLO stock?

The largest reported owner of Allogene Therapeutics, Inc. (ALLO) is BlackRock, Inc., with 12.4% of the company. In total, 207 funds and institutions reported holding ALLO at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ALLO insiders buying or selling?

In the last 12 months, ALLO insiders reported no open-market purchases and 15 sales worth $669K. The latest trade was on Oct 21, 2026. See every trade.

What is the short interest in ALLO?

As of Oct 30, 2026, 51.29M ALLO shares were sold short, 14.8% of the shares outstanding, down 4.0% from the report before. At the average daily volume of 8.27M shares, buying them all back would take about 6.2 trading days (days to cover). See the history.

Which famous investors hold ALLO?

4 of the 50 well-known investors we track reported ALLO in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $39.3M. See all holders.

Executive pay

Allogene Therapeutics's chief executive was paid a total of $6.1M for the year ended Dec 31, 2025, up 37% from $4.5M the year before. In the last 12 months, Allogene Therapeutics's executives and directors bought no stock on the open market and sold $669K.

Chief executive, total pay$6.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.9MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.